Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN

The TP53 and PTEN tumour suppressor genes are inactivated by nonsense mutations in a significant fraction of human tumours. TP53 nonsense mutant tumours account for approximately one million new cancer cases per year worldwide. We have screened chemical libraries with the aim of identifying compound...

Descripción completa

Detalles Bibliográficos

Autores principales:	Angelos Heldin, Matko Cancer, Mireia Palomar-Siles, Susanne Öhlin, Meiqiongzi Zhang, Alexander Sun-Zhang, Anna Mariani, Jianping Liu, Vladimir J.N. Bykov, Klas G. Wiman
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2023-12-01
Colección:	RNA Biology
Materias:	tp53 pten nonsense mutation novel compounds translational readthrough synergy
Acceso en línea:	http://dx.doi.org/10.1080/15476286.2023.2222250
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!